Reactome | IFNAR1:TYK2 binds TYK2 inhibitors

IFNAR1:TYK2 binds TYK2 inhibitors

Stable Identifier

R-HSA-9678737

Type

Reaction [binding]

Species

Homo sapiens

Compartment

cytosol, plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Non-receptor tyrosine-protein kinase TYK2 binds and is inhibited by several small molecule drugs (Clark et al. 2014, Gibbons et al. 2012). TYK2 is related to the Janus kinases (JAKs) family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Richardson et al. 2020, Stebbing et al. 2020).

Literature References

PubMed ID	Title	Journal	Year
24417533	Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases Clark, JD, Telliez, JB, Flanagan, ME	J. Med. Chem.	2014
32113509	COVID-19: combining antiviral and anti-inflammatory treatments Oechsle, O, Phelan, A, Tucker, C, Richardson, P, Stebbing, J, Smith, D, Griffin, I	Lancet Infect Dis	2020
23061660	Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors Chang, C, Siu, M, Murray, J, Sampath, D, Rawson, T, Ultsch, M, Hurley, CA, Gibbons, P, Pastor, RM, Eigenbrot, C, Zhou, A, Morris, C, Barrett, K, Kenny, JR, Hanan, EJ, Flynn, S, Kulagowski, J, van Abbema, A, Blair, WS, Blaney, J, Lee, L, Magnuson, SR, Lyssikatos, JP	J. Med. Chem.	2012
32032529	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Oechsle, O, Phelan, A, Tucker, C, Stebbing, J, Richardson, P, Smith, D, Griffin, I	Lancet	2020